Clinical site roster completed for the pilot study, with 4 leaders in EBUS-TBNA bronchoscopy; the study will confirm product performance in a clinical setting

Completed $2.7M Regulation D funding round, projected to support the program through completion of the pivotal study in 2027

National phase entry for our Point of Care Detection of Stabilized Chemokine Proteins patent

Scott Muerhoff, Volwiler Distinguished Research Fellow, joins the Scientific Advisory Board

Sample characterization clinical study shows 93% accuracy compared with cytopathology

Time and Motion Study completed at 2 clinical sites, forming the basis for an expanded user needs analysis

Proprietary engineered antibodies completed

Clinical Study 1: initial results confirm sample characterization objectives

Senior Technical Advisor Mike Hale joins the Scientific Advisory Board

Clinical sample collection begins with Scripps Health; 15 patients enrolled

Medical University of South Carolina added as a clinical partner

Closed $2.3M Reg D funding round

Initial patient enrollment in clinical study

First clinical study launched

Second patent filed

EB-BIO patent license acquired

4,000th test cartridge completed

Industrial design contract signed

Reader partnership agreement established

Closed $1M seed round

Became a Creative Destruction Lab alumnus

Provisional patent filed

FDA pre-submission meeting held

Developed a 5-minute test prototype

First in-patient prototype test

Key opinion leaders signed

Developed an 8-minute test prototype

Company incorporated

Developed a 10-minute test prototype